• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.

作者信息

Pope Janet, Sawant Ruta, Tundia Namita, Du Ella X, Qi Cynthia Z, Song Yan, Tang Patrick, Betts Keith A

机构信息

University of Western Ontario, London, ON, Canada.

AbbVie, Inc., North Chicago, IL, USA.

出版信息

Adv Ther. 2021 May;38(5):2750-2756. doi: 10.1007/s12325-021-01642-9. Epub 2021 Mar 20.

DOI:10.1007/s12325-021-01642-9
PMID:33742364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8107153/
Abstract
摘要

相似文献

1
Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Adv Ther. 2021 May;38(5):2750-2756. doi: 10.1007/s12325-021-01642-9. Epub 2021 Mar 20.
2
Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.致编辑的信：关于JAK抑制剂治疗中重度类风湿关节炎的比较疗效：一项网状Meta分析
Adv Ther. 2021 May;38(5):2747-2749. doi: 10.1007/s12325-021-01641-w. Epub 2021 Mar 20.
3
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.在初治的类风湿关节炎患者中，与甲氨蝶呤相比，托法替布、巴瑞替尼、乌帕替尼和菲诺替尼的缓解率和低疾病活动率相对较高。
Pharmacology. 2023;108(6):589-598. doi: 10.1159/000527186. Epub 2023 Aug 17.
4
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.比较中重度类风湿关节炎 JAK 抑制剂的疗效：网络荟萃分析。
Adv Ther. 2020 May;37(5):2356-2372. doi: 10.1007/s12325-020-01303-3. Epub 2020 Apr 15.
5
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
6
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
7
Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.与肿瘤坏死因子抑制剂相比，类风湿关节炎患者中JAK抑制剂或托珠单抗类药物的心血管安全性：随机临床试验的系统评价以及传统和贝叶斯网络荟萃分析
Semin Arthritis Rheum. 2024 Dec;69:152563. doi: 10.1016/j.semarthrit.2024.152563. Epub 2024 Oct 2.
8
Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs.类风湿关节炎药物疗效的网状荟萃分析解读。
J Clin Pharm Ther. 2021 Dec;46(6):1485-1488. doi: 10.1111/jcpt.13379. Epub 2021 Feb 7.
9
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎：系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
10
The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.不同 Janus 激酶抑制剂单药治疗类风湿关节炎的疗效和安全性：一项贝叶斯网状荟萃分析。
PLoS One. 2024 Jun 21;19(6):e0305621. doi: 10.1371/journal.pone.0305621. eCollection 2024.

本文引用的文献

1
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.托法替布、巴瑞替尼、乌帕替尼和非戈替尼与阿达木单抗相比在活动性类风湿关节炎患者中的相对疗效和安全性。
Z Rheumatol. 2020 Oct;79(8):785-796. doi: 10.1007/s00393-020-00750-1.